-
Mashup Score: 9Semaglutide cuts cardiovascular risk by 20% in people with heart disease, obesity: SELECT - 1 year(s) ago
PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.“Semaglutide 2.4 mg is the first weight-management therapy … proven in a rigorous randomized controlled trial to reduce the risk of cardiovascular
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 9Semaglutide cuts cardiovascular risk by 20% in people with heart disease, obesity: SELECT - 1 year(s) ago
PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.“Semaglutide 2.4 mg is the first weight-management therapy … proven in a rigorous randomized controlled trial to reduce the risk of cardiovascular
Source: www.healio.comCategories: General Medicine News, Cardiology News and JournTweet-
RT @ErinMichos: My perspective on #SELECT trial for @CardiologyToday: https://t.co/C7Lfi5f4sV
-
-
Mashup Score: 18Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics - 1 year(s) ago
Objective This paper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovas…
Source: onlinelibrary.wiley.comCategories: Cardiologists, Latest HeadlinesTweet-
#Semaglutide 2.4 mg reduces the risk of MACE by 20% in adults with overweight or obesity in the #SELECT trial SELECT study baseline characteristics 👇🏻 https://t.co/qLuCHVNPs2 @novonordisk announced the headline results from the SELECT CV outcomes trial. 👇🏻… https://t.co/mgWUYPos0y https://t.co/gnOscKoPeQ
-
-
Mashup Score: 1
Ongoing trials like SELECT that are aimed at CV outcomes “will certainly change the cardiovascular disease landscape,” says Sean Heffron.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar Ongoing trials like #SELECT that are aimed at CV outcomes “will certainly change the cardiovascular disease landscape @TCTMD @mmamas1973 @ShelleyWood2 https://t.co/aMcO9y4YO5
-
-
Mashup Score: 1A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) - Full Text View - ClinicalTrials.gov - 2 year(s) ago
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) – Full Text View.
Source: clinicaltrials.govCategories: Cardiologists, Latest HeadlinesTweet-
Another ongoing trial with #SELECT study in La Pitié https://t.co/QpQU4Pf9uS #semaglutid #weightloss #T2D
-
-
Mashup Score: 0
Background In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15 mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% improvement in American College of Rheumatology (ACR) criteria at 12 weeks in patients with psoriatic arthritis (PsA). Here, we report 56-week efficacy and safety in patients from SELECT-PsA 1. Methods Patients received upadacitinib…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet-
Results weeks 24 to 56 of the #SELECT-PsA 1 study: - placebo to #upadacitinib switcher had comparable results to those orginally starting upa - Results of 24 could be maintained into 56 w. - Superiority of upa 15/30mg over adalimumab at 56 w in ACR20/50/70 https://t.co/8WVc3eFiJp https://t.co/VSYzqBkSJj
-
-
Mashup Score: 2Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists - PubMed - 4 year(s) ago
Obesity is a chronic disease associated with many complications. Weight loss of 5-15% can improve many obesity-related complications. Despite the benefits of weight reduction, there are many challenges in losing weight and maintaining long-term weight loss. Pharmacotherapy can help people with obesi …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
Ongoing trial #SELECT at La Pitié. Not completely "double blinded" as some patients have a weight loss >10 kg whereas others not.#Weight Loss and Maintenance Related to the Mechanism of Action of #GLP1RA https://t.co/7J9TZguejb
-
-
Mashup Score: 0Early Infarct Growth Rate Correlation With Endovascular Thrombectomy Clinical Outcomes - 4 year(s) ago
Background and Purpose: Time elapsed from last-known well (LKW) and baseline imaging results are influential on endovascular thrombectomy (EVT) outcomes. Methods: In a prospective multicenter cohort
Source: StrokeCategories: Latest Headlines, NeurologyTweet-
#STROKE Early Infarct Growth Rate strongly correlates with both collateral status and clinical outcomes after #MechanicalThrombectomy in #LVO stroke patients @amrsarrajMD @AmeerEHassan #SELECT investigators https://t.co/73qRytOuU9 https://t.co/ftvumRGrff
-
-
Mashup Score: 1
Our office is committed to helping our patients understand their injuries and treatments. Learn more about our patient’s experiences with Dr. Ahmad.
Source: Dr. Christopher S AhmadCategories: Latest Headlines, OrthopedicsTweet-
🙌 Our #office is #committed to #helping our #patients fully understand their #injuries and their #treatment #options ! ✅ #Select a patient below to #learn more about their #injury and their #experience with #TeamAhmad: https://t.co/NG1djZKHzX @nyphospital @OrthoColumbia
-
RT @ErinMichos: My perspective on #SELECT trial for @CardiologyToday: https://t.co/C7Lfi5f4sV